Polyrizon Advances Nasarix Study With 3 Major US Trial Sites

MT Newswires Live06-08

Polyrizon (PLRZ) has secured agreements with three US clinical sites for its upcoming Nasarix trial, marking a key step toward initiating its multi-center study in seasonal allergic rhinitis, the company said Monday.

The sites represent major enrollment centers expected to support patient recruitment for the study evaluating the safety, tolerability and efficacy of its intranasal hydrogel allergy blocker.

Polyrizon said the trial will compare Nasarix with saline spray in patients with seasonal allergic rhinitis, with up to five US sites expected to participate in total.

Shares of Polyrizon were down more than 3% in Monday trading.

Price: 12.73, Change: -0.48, Percent Change: -3.63

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641915487?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-08 21:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641915487","market":"nz","top_or_hot":-1,"title":"Polyrizon Advances Nasarix Study With 3 Major US Trial Sites","media":"MT Newswires Live","content":"<html><body><p> Polyrizon (PLRZ) has secured agreements with three US clinical sites for its upcoming Nasarix trial, marking a key step toward initiating its multi-center study in seasonal allergic rhinitis, the company said Monday.</p><p>The sites represent major enrollment centers expected to support patient recruitment for the study evaluating the safety, tolerability and efficacy of its intranasal hydrogel allergy blocker.</p><p>Polyrizon said the trial will compare Nasarix with saline spray in patients with seasonal allergic rhinitis, with up to five US sites expected to participate in total.</p><p>Shares of Polyrizon were down more than 3% in Monday trading.</p><p>Price: 12.73, Change: -0.48, Percent Change: -3.63</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Polyrizon Advances Nasarix Study With 3 Major US Trial Sites</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPolyrizon Advances Nasarix Study With 3 Major US Trial Sites\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-08 21:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Polyrizon (PLRZ) has secured agreements with three US clinical sites for its upcoming Nasarix trial, marking a key step toward initiating its multi-center study in seasonal allergic rhinitis, the company said Monday.</p><p>The sites represent major enrollment centers expected to support patient recruitment for the study evaluating the safety, tolerability and efficacy of its intranasal hydrogel allergy blocker.</p><p>Polyrizon said the trial will compare Nasarix with saline spray in patients with seasonal allergic rhinitis, with up to five US sites expected to participate in total.</p><p>Shares of Polyrizon were down more than 3% in Monday trading.</p><p>Price: 12.73, Change: -0.48, Percent Change: -3.63</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2641915487","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2641915487","pubTimestamp":1780926678,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Polyrizon  has secured agreements with three US clinical sites for its upcoming Nasarix trial, marking a key step toward initiating its multi-center study in seasonal allergic rhinitis, the company said Monday.The sites represent major enrollment centers expected to support patient recruitment for the study evaluating the safety, tolerability and efficacy of its intranasal hydrogel allergy blocker.Polyrizon said the trial will compare Nasarix with saline spray in patients with seasonal allergic rhinitis, with up to five US sites expected to participate in total.Shares of Polyrizon were down more than 3% in Monday trading.Price: 12.73, Change: -0.48, Percent Change: -3.63","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PLRZ":"Polyrizon Ltd."},"translate_title":"Polyrizon与美国3个主要试验点推进Nasarix研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLRZ":1},"content_text":"Polyrizon (PLRZ) has secured agreements with three US clinical sites for its upcoming Nasarix trial, marking a key step toward initiating its multi-center study in seasonal allergic rhinitis, the company said Monday.The sites represent major enrollment centers expected to support patient recruitment for the study evaluating the safety, tolerability and efficacy of its intranasal hydrogel allergy blocker.Polyrizon said the trial will compare Nasarix with saline spray in patients with seasonal allergic rhinitis, with up to five US sites expected to participate in total.Shares of Polyrizon were down more than 3% in Monday trading.Price: 12.73, Change: -0.48, Percent Change: -3.63","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641915487","isCrawlerRequest":true}